These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 25524609)
1. The DEK oncoprotein is upregulated by multiple leukemia-associated fusion genes. Sandén C; Nilsson HJ; Gullberg U Blood Cells Mol Dis; 2015 Mar; 54(3):284-5. PubMed ID: 25524609 [No Abstract] [Full Text] [Related]
2. The DEK oncoprotein and its emerging roles in gene regulation. Sandén C; Gullberg U Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544 [TBL] [Abstract][Full Text] [Related]
3. The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK. Ageberg M; Gullberg U; Lindmark A Haematologica; 2006 Feb; 91(2):268-9. PubMed ID: 16461319 [TBL] [Abstract][Full Text] [Related]
4. Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093 [TBL] [Abstract][Full Text] [Related]
5. Role of the DEK oncogene in the development of squamous cell carcinoma. Ishida K; Nakashima T; Shibata T; Hara A; Tomita H Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741 [TBL] [Abstract][Full Text] [Related]
6. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib. Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585 [No Abstract] [Full Text] [Related]
8. Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN. Fornerod M; Boer J; van Baal S; Morreau H; Grosveld G Oncogene; 1996 Oct; 13(8):1801-8. PubMed ID: 8895527 [TBL] [Abstract][Full Text] [Related]
9. Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease. e Moura de Souza CL; Bub CB; Torres MA; Velloso ED; Silveira PA; Correia RP; Bacal NS; Mangueira CL; Fernandes JF; Odone Filho V; Hamerschlak N; Campregher PV J Clin Pathol; 2015 Nov; 68(11):950-2. PubMed ID: 26193901 [No Abstract] [Full Text] [Related]
10. Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK. Ko SI; Lee IS; Kim JY; Kim SM; Kim DW; Lee KS; Woo KM; Baek JH; Choo JK; Seo SB FEBS Lett; 2006 May; 580(13):3217-22. PubMed ID: 16696975 [TBL] [Abstract][Full Text] [Related]
11. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. Wise-Draper TM; Allen HV; Thobe MN; Jones EE; Habash KB; Münger K; Wells SI J Virol; 2005 Nov; 79(22):14309-17. PubMed ID: 16254365 [TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. Kim DW; Chae JI; Kim JY; Pak JH; Koo DB; Bahk YY; Seo SB J Cell Biochem; 2009 Apr; 106(6):1048-59. PubMed ID: 19229864 [TBL] [Abstract][Full Text] [Related]
13. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Shibata T; Kokubu A; Miyamoto M; Hosoda F; Gotoh M; Tsuta K; Asamura H; Matsuno Y; Kondo T; Imoto I; Inazawa J; Hirohashi S Oncogene; 2010 Aug; 29(33):4671-81. PubMed ID: 20543864 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma. Yi HC; Liu YL; You P; Pan JS; Zhou JY; Liu ZJ; Zhang ZY Mol Med Rep; 2015 Feb; 11(2):1318-23. PubMed ID: 25351213 [TBL] [Abstract][Full Text] [Related]
15. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Sitwala KV; Adams K; Markovitz DM Oncogene; 2002 Dec; 21(57):8862-70. PubMed ID: 12483538 [TBL] [Abstract][Full Text] [Related]
16. The distribution of the DEK protein in mammalian chromatin. Hu HG; Scholten I; Gruss C; Knippers R Biochem Biophys Res Commun; 2007 Jul; 358(4):1008-14. PubMed ID: 17524367 [TBL] [Abstract][Full Text] [Related]
17. The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin. Waldmann T; Scholten I; Kappes F; Hu HG; Knippers R Gene; 2004 Dec; 343(1):1-9. PubMed ID: 15563827 [TBL] [Abstract][Full Text] [Related]
18. Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms. Piredda ML; Catalano G; Ciardi C; Divona M; Cicconi L; Panetta P; Curzi P; Garza E; Martínez-Losada C; Postorino M; Lo-Coco F; Noguera NI Ann Hematol; 2017 Jan; 96(1):155-157. PubMed ID: 27734129 [No Abstract] [Full Text] [Related]
19. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Ballerini P; Busson M; Fasola S; van den Akker J; Lapillonne H; Romana SP; Marynen P; Bernard OA; Landman-Parker J; Berger R Leukemia; 2005 Mar; 19(3):468-70. PubMed ID: 15674415 [No Abstract] [Full Text] [Related]
20. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Fornerod M; Boer J; van Baal S; Jaeglé M; von Lindern M; Murti KG; Davis D; Bonten J; Buijs A; Grosveld G Oncogene; 1995 May; 10(9):1739-48. PubMed ID: 7753551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]